ArticleCancer letters2022
PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Open access · hybridAbstract read
In one paragraph
Article in Cancer letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Neural regulation in lung cancer: from mechanisms to new therapeutic perspectives.Clinical and experimental medicine · 2026Review
- The association betweenFrontiers in genetics · 2026Article
- GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.Hepatology (Baltimore, Md.) · 2025Article
- Protein Kinase C Family: Structures, Biological Functions, Diseases, and Pharmaceutical Interventions.MedComm · 2025Review
- The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies.NPJ precision oncology · 2025Review
- The gut microbiome enhances breast cancer immunotherapy following bariatric surgery.JCI insight · 2025Article
- Advancing breast cancer biomarkers: a centromere-related gene signature integrated with single-cell analysis for prognostic prediction.Frontiers in immunology · 2025Article
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.npj metabolic health and disease · 2025Article
- The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers.Frontiers in immunology · 2025Review
- Integrative bioinformatics analysis for identifying the mitochondrial-related gene signature associated with immune infiltration in premature ovarian insufficiency.BMC medicine · 2024Article
- Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert "Cold" Tumors to "Hot" Tumors.International journal of molecular sciences · 2024Review
- FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden.Cancers · 2024Article
- Protein kinase C delta regulates mononuclear phagocytes and hinders response to immunotherapy in cancer.Science advances · 2023Article
- Article
- Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response.Biology · 2023Review
- Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions.Pharmacology & therapeutics · 2023Review
- MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Mehdi ChaibDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Laura M SipeDepartment of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Johnathan R YarbroDepartment of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Margaret S BohmDepartment of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Brittany R CountsDivision of Regenerative and Rehabilitation Sciences, College of Health Professions, UTHSC Memphis, USA.
Ubaid TanveerDepartment of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Ajeeth K PingiliDepartment of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Deidre DariaOffice of Vice Chancellor for Research, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Tony N MarionDepartment of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Office of Vice Chancellor for Research, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
James A CarsonDivision of Regenerative and Rehabilitation Sciences, College of Health Professions, UTHSC Memphis, USA; UTHSC Center for Cancer Research, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Paul G ThomasDepartment of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA; UTHSC Center for Cancer Research, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Liza MakowskiDepartment of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Department of Medicine, Division of Hematology and Oncology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Department of Microbiology, Immunology, and Biochemistry, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA; UTHSC Center for Cancer Research, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA. Electronic address: liza.makowski@uthsc.edu.
University of Tennessee Health Science Center · USSt. Jude Children's Research Hospital · US
Funding
Role of microbial-modulated bile acid receptor signaling in breast cancerR01CA253329 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Katherine Loree Cook, Liza Makowski-Hayes · 2020 to 2026
$3.0MTransdisciplinary Research in Energetics and Cancer (TREC) Training GrantR25CA203650 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L · 2016 to 2025
$2.9MObesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial CancerR37CA226969 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BAE-JUMP, VICTORIA LIN · 2018 to 2024
$2.5MDetermining susceptibility loci in triple negative breast cancer using a novel pre-clinical modelR01CA262112 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Liza Makowski-Hayes · 2022 to 2026
$2.0MThe role of bile acids to ameliorate obesity driven triple negative breast cancerF32CA250192 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SIPE, LAURA MARIE · 2021 to 2022
$80kPKC agonism restricts innate immune suppression and promotes antigen cross-presentation in Triple Negative Breast CancerF31CA268871 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CHAIB, MEHDI · 2022 to 2022
$33kNCI NIH HHS F31 CA268871NCI NIH HHS F32 CA250192NCI NIH HHS R01 CA253329NCI NIH HHS R01 CA262112NCI NIH HHS R25 CA203650NCI NIH HHS R37 CA226969
Abstract
Myeloid-derived suppressor cells (MDSCs) are an immature innate cell population that expands in pathological conditions such as cancer and suppresses T cells via production of immunosuppressive factors. Conversely, efficient cytotoxic T cell priming is dependent on the ability of antigen-presenting cells (APCs) to cross-present tumor antigens to CD8
Indexed as
Breast NeoplasmsCross-PrimingAnimalsCD40 AntigensCD8-Positive T-LymphocytesDendritic CellsFemaleHumansImmunity, InnateMiceTumor MicroenvironmentCD40 AntigensCD40Cross-presentationDCMDSCPKC
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.